The Cambridge site of an international biotechnology company will cease manufacturing, leaving 150 people without a job.

Co-authors reported grants from Takeda Pharmaceuticals and UCB, consulting for GlaxoSmithKline, and personal fees from the ...

Most Oncologic Drugs Advisory Committee members took issue with the lack of dosing optimization and the lack of US patient ...

British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March ...

GlaxoSmithKline LLC (GSK) plans to lay off 150 Cambridge workers. The layoffs come months after GSK said it had planned to ...

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity ...

Biogen is investing $2 billion in its U.S. manufacturing footprint — but not in Massachusetts, where the drug company is ...

In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy ...

Arizona Attorney General Kris Mayes says the pharmaceutical company GlaxoSmithKline manipulated patents to reduce ...

GSK plc (NYSE:GSK) is one of the best cheap stocks under $50 to buy now. On July 15, BofA analyst Sachin Jain maintained a ...

AdFalciVax may offer advantages such as broader protection and a lower risk of immune evasion compared to existing ...

Martha Sazon, president and chief executive of Mynt, the company behind mobile wallet GCash, has been instrumental in ...